Table 2

Contribution of selected factors on the magnitude of the ORsa for the association between the p53 codon 72 polymorphism and cervical neoplasia: results from meta-regression

Study design characteristicContrastRatio of odds ratios (95% confidence interval)
ICC (n = 24)SCC (n = 22)HSIL (n = 22)LSIL (n = 18)
Year of publication2000s vs. 1990s0.89 (0.64–1.24)1.40 (0.85–2.30)1.13 (0.86–1.49)1.23 (0.86–1.78)
Geographical region of studyEurope vs. Other regions1.00 (0.68–1.45)0.94 (0.56–1.61)1.09 (0.84–1.41)0.86 (0.59–1.26)
Control group in Hardy-Weinberg equilibriumNot in equilibrium vs. in equilibrium1.46 (1.05–2.02)2.28 (1.34–3.86)1.23 (0.96–1.57)1.05 (0.61–1.80)
Sampling of control groupConvenience vs. risk-based1.26 (0.89–1.77)1.43 (0.89–2.30)0.94 (0.72–1.23)1.11 (0.75–1.64)
Control for ethnicity/raceUncontrolled vs. controlled0.91 (0.63–1.32)0.78 (0.46–1.31)0.90 (0.69–1.17)0.76 (0.54–1.09)
Genotyping method utilizedAllele-specific PCR vs. other1.35 (0.98–1.86)1.06 (0.63–1.76)0.99 (0.76–1.28)0.99 (0.68–1.42)
One method vs. > one method1.15 (0.67–1.98)1.01 (0.49–2.07)1.37 (0.84–2.25)1.07 (0.62–1.84)
Restriction of case groupHigh-risk HPV+ vs. unrestricted0.78 (0.53–1.14)1.99 (1.24–3.19)1.03 (0.79–1.35)0.90 (0.58–1.41)
DNA source used for case groupCervical tissue vs. blood1.15 (0.82–1.61)0.92 (0.51–1.65)0.99 (0.76–1.31)1.33 (0.82–2.16)
Archival vs. fresh tissue1.47 (0.86–2.54)0.98 (0.46–2.10)1.35 (1.02–1.80)1.40 (0.95–2.09)
DNA source used for controlsArchival vs. fresh tissue1.29 (0.63–2.64)1.25 (0.62–2.51)1.02 (0.73–1.45)0.89 (0.57–1.39)
  • a OR, odds ratio; ICC, invasive cervical cancer; SCC, squamous cell carcinoma; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.